Abstract:Glial fibrillary acidic protein (GFAP) is a well‐established biomarker of reactive astrogliosis in the central nervous system. In this review, we explore how the physicochemical characteristics of GFAP may influence its detection, which may underlie the differential diagnostic performance of GFAP in different biological fluids and can provide valuable insights into underlying biological processes. We summarise how knowledge of GFAP biology and proteoforms, including isoforms, post‐translational modifications, discharge mechanisms, breakdown products, higher‐order species and interacting partners, can be utilised to guide future biomarker test development and enhance disease pathology comprehension. Glial fibrillary acidic protein (GFAP) is a well‐established biomarker of reactive astrogliosis in the central nervous system because of its elevated levels following brain injury and various neurological disorders. The advent of ultra‐sensitive methods for measuring low‐abundant proteins has significantly enhanced our understanding of GFAP levels in the serum or plasma of patients with diverse neurological diseases. Clinical studies have demonstrated that GFAP holds promise both as a diagnostic and prognostic biomarker, including but not limited to individuals with Alzheimer's disease. GFAP exhibits diverse forms and structures, herein referred to as its proteoform complexity, encompassing conformational dynamics, isoforms and post‐translational modifications (PTMs). In this review, we explore how the proteoform complexity of GFAP influences its detection, which may affect the differential diagnostic performance of GFAP in different biological fluids and can provide valuable insights into underlying biological processes. Additionally, proteoforms are often disease‐specific, and our review provides suggestions and highlights areas to focus on for the development of new assays for measuring GFAP, including isoforms, PTMs, discharge mechanisms, breakdown products, higher‐order species and interacting partners. By addressing the knowledge gaps highlighted in this review, we aim to support the clinical translation and interpretation of GFAP in both CSF and blood and the development of reliable, reproducible and specific prognostic and diagnostic tests. To enhance disease pathology comprehension and optimise GFAP as a biomarker, a thorough understanding of detected proteoforms in biofluids is essential.

GFAP-isoforms in the nervous system: Understanding the need for diversity

Alterations in expression of GFAPmRNA and correlated protein after cerebral ischemia/reperfusion in rats

The GFAP proteoform puzzle: How to advance GFAP as a fluid biomarker in neurological diseases

Glial Fibrillary Acidic Protein: Regulation by Hormones, Cytokines, and Growth Factors

Characterisation of GFAP-Expressing Glial Cells in the Dorsal Root Ganglion after Spared Nerve Injury

Hormones and growth factors induce the synthesis of glial fibrillary acidic protein in rat brain astrocytes

14-3-3Γ Affects Dynamics and Integrity of Glial Filaments by Binding to Phosphorylated GFAP

The molecular cloning of glial fibrillary acidic protein in Gekko japonicus and its expression changes after spinal cord transection

Gfap Expression in Injured Astrocytes in Rats

GFAP expression in the BRAIN during human postnatal development

Serial Deletion Reveals Structural Basis and Stability for the Core Enzyme Activity of Human Glutaminase 1 Isoforms: Relevance to Excitotoxic Neurodegeneration.

Tissue expression of alternatively spliced GFRα1, NCAM and RET isoforms and the distinct functional consequence of ligand-induced activation of GFRα1 isoforms

New insights into neuropathology and pathogenesis of autoimmune glial fibrillary acidic protein meningoencephalomyelitis

Serological Biomarkers in Autoimmune GFAP Astrocytopathy.

Reactive glial cells: increased stiffness correlates with increased intermediate filament expression.

Age-specific control and Alzheimers disease reference curves and z-scores for glial fibrillary acidic protein in blood

NG2 and GFAP co-expression after differentiation in cells transfected with mutant GFAP and in undifferentiated glioma cells

Regionally diverse astrocyte subtypes and their heterogeneous response to EAE

Membrane properties and coupling of macroglia in the optic nerve

Association of plasma glial fibrillary acidic protein (GFAP) with neuroimaging of Alzheimer's disease and vascular pathology

Glial Fibrillary Acidic Protein Astrocytopathy: Review of Pathogenesis, Imaging Features, and Radiographic Mimics